EANS-News: SYGNIS Pharma AG Shareholders support management proposals at
SYGNIS Pharma´s AGM with overwhelming majority
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Annual & Special Corporate Meetings
Heidelberg (euro adhoc) - Shareholders support management proposals at SYGNIS
Pharma´s AGM with overwhelming majority
Heidelberg, 25 November 2011 - At today´s Annual General Meeting (AGM) of
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard)
shareholders representing about 73 percent of the capital approved all
proposals of the Management with an overwhelming majority. Main decisions were
related to the discharge of the members of the Supervisory and the Management
Board for the past Fiscal Year, the election of the members of the Supervisory
Board as well as the creation of contingent capital for convertible bonds.
All members of the Supervisory Board have been re-elected, with the exception
of Mr. Friedrich Christ. Mr. Christ has meanwhile retired and it was his
personal decision not to stand for re-election. From today´s AGM onwards,
Dr. Wolf-Dieter Starp, Head of Global M&A at BASF SE, has been
elected to the Supervisory Board.
Prof. Dr. Friedrich von Bohlen und Halbach, chairman of the Supervisory Board
thanked Mr. Christ for his work and efforts during the last years for SYGNIS
Pharma AG. He welcomed Dr. Starp as a new member of the Supervisory Board.
At the AGM the two members of the Management Board, Peter Willinger and Dr.
Frank Rathgeb, confirmed that the data on SYGNIS´ current AXIS 2 efficacy study
for AX200 for the treatment of acute stroke is expected to be published in
December 2011.
About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical
company listed on the Prime Standard of the German stock exchange. The Company
is focused on the research, development and marketing of innovative therapies
for the treatment of disorders of the Central Nervous System. These include
Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting from
injuries to the brain or spinal cord. All these disorders are characterized by
the fact that, as the disease progresses, nerve cells are damaged and die.
Although there is great medical demand, there are currently no or only
inadequate treatment options available.
For further information please contact:
SYGNIS Pharma AG:
|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |
Media-Contact:
Julia Phillips
FTI Consulting
Tel.: +44 (0) 20 7269 7187
###
Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.
###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English